Researchers and clinicians at WashU Medicine are helping reshape how hepatitis C virus (HCV) is treated during pregnancy, with a new study showing that a commonly used antiviral regimen can be used safely and effectively in pregnant patients in real-world care.
The study, led by Laura Marks, MD, PhD, and Madeline McCrary, MD, examined the use of glecaprevir-pibrentasvir, an oral HCV treatment, in 14 pregnant patients treated between 14 and 32 weeks of gestation. Of the 14 patients prescribed the medication, ten completed the treatment. All ten of those patients achieved virologic response by the time of delivery or earlier. Investigators reported no maternal or neonatal safety concerns, adding to growing evidence that HCV treatment during pregnancy may be feasible when carefully managed through shared decision-making. Their findings are published Aug. 11 in Clinical Infectious Diseases.
The findings are especially meaningful because, until now, there had been no clinical trial data and no real-world experience published for glecaprevir-pibrentasvir treatment in pregnancy. The study helps fill an important gap for clinicians caring for pregnant patients with HCV, a population that has historically had limited treatment options during pregnancy despite the potential benefits of reducing maternal infection and preventing transmission to infants.
Read more on the Division of Infectious Diseases website.